Novel AI-Powered Multimodal Model Seeks to Predict TACE-Immunotherapy Response in Hepatocellular Carcinoma — 1,170-Patient Study Opens

References

1. 1.European Association for the Study of the Liver. (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 69(1), 182-236. https://doi.org/10.1016/j.jhep.2018.03.019
2. 2.Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., ... & Cheng, A. L. (2020). Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New England Journal of Medicine, 382(20), 1894-1905. https://doi.org/10.1056/NEJMoa1915745
3. 3.Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., ... & Finn, R. S. (2021). Hepatocellular carcinoma. Nature Reviews Disease Primers, 7(1), 6. https://doi.org/10.1038/s41572-020-00240-3
4. 4.Rimassa, L., Personeni, N., Czauderna, C., Foerster, F., & Galle, P. R. (2019). Systemic treatment of HCC in special populations. Journal of Hepatology, 71(4), 931-940. https://doi.org/10.1016/j.jhep.2019.06.012
5. 5.Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249. https://doi.org/10.3322/caac.21660
6. 6.Teng, G. (2024). Artificial Intelligence-Based Multimodal Data Integration for Tumor Microenvironment Analysis and Response Prediction in Hepatocellular Carcinoma Patients Undergoing TACE Combined With Immunotherapy and Targeted Therapy [Clinical trial registration NCT07584317]. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07584317